|
|
||||||||
Clinical Chemistry, Vol 34, 1575-1578, Copyright © 1988 by American Association for Clinical Chemistry
P Koskinen
Central Laboratory, University Central Hospital of Turku, Finland.
I evaluated the between-method variation of C-peptide determined with C- peptide radioimmunoassay kit reagents from Mallinckrodt, Behring, Diagnostic Products Corp., and Immuno Nuclear Corp., and antisera from Novo (M1230, M1221, and K6) and Cambridge Medical Diagnostics (299- 029P). C-peptide concentrations corresponding to 0.6 nmol/L (as determined with M1230) ranged from 0.54 (by Immuno Nuclear Corp.) to 1.06 nmol/L (by M1221). Furthermore, pretreating plasma specimens with Polyethylene Glycol 6000 variably decreased the results. Several factors may contribute to the between-method variation of C-peptide analyses: differences in the specificity of antisera, the type of C- peptide preparation used as standard and tracer, liability of the immunoassay to nonspecific interference, and possibly the heterogeneity of C-peptide immunoreactivity in the specimens.
The following articles in journals at HighWire Press have cited this article:
![]() |
D. Rodriguez Cabaleiro, D. Stockl, J. M. Kaufman, T. Fiers, and L. M. Thienpont Feasibility of Standardization of Serum C-Peptide Immunoassays with Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry Clin. Chem., June 1, 2006; 52(6): 1193 - 1196. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |